US6872699B2
(en)
|
1992-11-13 |
2005-03-29 |
Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften, E.V. |
Truncated Flk-1 receptor protein, methods of use and a recombinant vector containing a nucleotide encoding the truncated Flk-1 protein
|
US6177401B1
(en)
|
1992-11-13 |
2001-01-23 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften |
Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
|
US5837815A
(en)
*
|
1994-12-15 |
1998-11-17 |
Sugen, Inc. |
PYK2 related polypeptide products
|
US5880141A
(en)
*
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
US6846839B1
(en)
*
|
1995-06-07 |
2005-01-25 |
Sugen, Inc. |
Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis
|
US6906093B2
(en)
|
1995-06-07 |
2005-06-14 |
Sugen, Inc. |
Indolinone combinatorial libraries and related products and methods for the treatment of disease
|
US6316635B1
(en)
*
|
1995-06-07 |
2001-11-13 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
US6147106A
(en)
*
|
1997-08-20 |
2000-11-14 |
Sugen, Inc. |
Indolinone combinatorial libraries and related products and methods for the treatment of disease
|
ATE253908T1
(en)
*
|
1995-08-16 |
2003-11-15 |
Huntington Medical Res Inst |
RHODAMINE 123 COMPOSITIONS FOR TREATMENT OF PROSTATE CANCER
|
ATE243034T1
(en)
*
|
1996-01-17 |
2003-07-15 |
Taiho Pharmaceutical Co Ltd |
INTIMAL THICKENING INHIBITORS
|
TR199801929T2
(en)
*
|
1996-03-29 |
1998-12-21 |
Pfizer Inc. |
Benzyl(ide)-lactam derivatives, their use as (anti)agonists of the 5-HT1A receptors.
|
US6696448B2
(en)
|
1996-06-05 |
2004-02-24 |
Sugen, Inc. |
3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors
|
US6682921B1
(en)
|
1996-08-21 |
2004-01-27 |
New York University |
Crystals of the tyrosine kinase domain of non-insulin receptor tyrosine kinases
|
WO1998007695A1
(en)
*
|
1996-08-23 |
1998-02-26 |
Sugen, Inc. |
Indolinone combinatorial libraries and related products and methods for the treatment of disease
|
WO1998024432A2
(en)
*
|
1996-12-05 |
1998-06-11 |
Sugen, Inc. |
Use of indolinone compounds as modulators of protein kinases
|
ES2227729T3
(en)
*
|
1996-12-11 |
2005-04-01 |
Sugen, Inc. |
SCREENING METHODS FOR COMPOUNDS UNITED TO PYK2 POLYPEPTIDE.
|
US6248771B1
(en)
|
1997-03-05 |
2001-06-19 |
Sugen, Inc. |
Formulations for hydrophobic pharmaceutical agents
|
AR012634A1
(en)
|
1997-05-02 |
2000-11-08 |
Sugen Inc |
QUINAZOLINE BASED COMPOUND, FAMACEUTICAL COMPOSITION THAT UNDERSTANDS IT, METHOD TO SYNTHESIZE IT, ITS USE, METHODS OF MODULATION OF THE DESERINE / TREONIN PROTEIN-KINASE FUNCTION AND IN VITRO METHOD TO IDENTIFY COMPOUNDS THAT MODULATE
|
WO1998050356A1
(en)
*
|
1997-05-07 |
1998-11-12 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
US6316429B1
(en)
|
1997-05-07 |
2001-11-13 |
Sugen, Inc. |
Bicyclic protein kinase inhibitors
|
US6486185B1
(en)
|
1997-05-07 |
2002-11-26 |
Sugen, Inc. |
3-heteroarylidene-2-indolinone protein kinase inhibitors
|
US6987113B2
(en)
|
1997-06-11 |
2006-01-17 |
Sugen, Inc. |
Tyrosine kinase inhibitors
|
US6114371A
(en)
*
|
1997-06-20 |
2000-09-05 |
Sugen, Inc. |
3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
|
US6313158B1
(en)
|
1997-06-20 |
2001-11-06 |
Sugen, Inc. |
Bioavailability of 3-heteroarylidenyl-2-indolinones active as protein tyrosine kinase inhibitors
|
TW527355B
(en)
*
|
1997-07-02 |
2003-04-11 |
Bristol Myers Squibb Co |
Inhibitors of farnesyl protein transferase
|
US6235769B1
(en)
*
|
1997-07-03 |
2001-05-22 |
Sugen, Inc. |
Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
|
GB9716557D0
(en)
|
1997-08-06 |
1997-10-08 |
Glaxo Group Ltd |
Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
|
US20040067531A1
(en)
*
|
1997-08-20 |
2004-04-08 |
Sugen, Inc. |
Methods of modulating protein tyrosine kinase function with substituted indolinone compounds
|
DE69838172T2
(en)
|
1997-08-22 |
2008-04-10 |
Astrazeneca Ab |
OXINDOLYLCHINAZOLE DERIVATIVES AS ANGIOGENESEHEMMER
|
GB9718913D0
(en)
|
1997-09-05 |
1997-11-12 |
Glaxo Group Ltd |
Substituted oxindole derivatives
|
UA72448C2
(en)
|
1997-09-26 |
2005-03-15 |
Zentaris Gmbh |
Azabenzimidazole-based compounds, methods for their synthesis and pharmaceutical composition, method for modulating function of serine/threonine protein kinases with azabenzimidazole-based compounds, method for identifying compounds modulating functioning of serine/threonine protein kinase, method for preventing and treating serine/threonine protein kinase-related abnormal conditions with azabenzimidazole-based compounds
|
US6133305A
(en)
|
1997-09-26 |
2000-10-17 |
Sugen, Inc. |
3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
|
UA71555C2
(en)
|
1997-10-06 |
2004-12-15 |
Zentaris Gmbh |
Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
|
US20030219380A1
(en)
*
|
1997-11-07 |
2003-11-27 |
Annie Fong |
Method of determining an efficacious dose of a drug
|
US8071384B2
(en)
*
|
1997-12-22 |
2011-12-06 |
Roche Diagnostics Operations, Inc. |
Control and calibration solutions and methods for their use
|
US7494816B2
(en)
|
1997-12-22 |
2009-02-24 |
Roche Diagnostic Operations, Inc. |
System and method for determining a temperature during analyte measurement
|
US6531502B1
(en)
|
1998-01-21 |
2003-03-11 |
Sugen, Inc. |
3-Methylidenyl-2-indolinone modulators of protein kinase
|
JP2002507598A
(en)
*
|
1998-03-26 |
2002-03-12 |
スージェン・インコーポレーテッド |
A family of heterocyclic compounds for regulating tyrosine protein kinase
|
US6514981B1
(en)
|
1998-04-02 |
2003-02-04 |
Sugen, Inc. |
Methods of modulating tyrosine protein kinase function with indolinone compounds
|
DE19816624A1
(en)
*
|
1998-04-15 |
1999-10-21 |
Boehringer Ingelheim Pharma |
Novel substituted indolinones, their preparation and their use as pharmaceuticals
|
US6569868B2
(en)
|
1998-04-16 |
2003-05-27 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
CO5031249A1
(en)
*
|
1998-05-29 |
2001-04-27 |
Sugen Inc |
PIRROL SUBSTITUTE-2-PROTEINCI-NASAS INHIBITING INDOLINONES
|
DE19824922A1
(en)
*
|
1998-06-04 |
1999-12-09 |
Boehringer Ingelheim Pharma |
Novel substituted indolinones, their preparation and their use as pharmaceuticals
|
US6319918B1
(en)
|
1998-06-04 |
2001-11-20 |
Boehringer Ingelheim Pharma Kg |
Substituted indolinones with kinase inhibitory activity
|
EP1117397A1
(en)
|
1998-08-31 |
2001-07-25 |
Sugen, Inc. |
Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity
|
ATE243195T1
(en)
*
|
1998-09-25 |
2003-07-15 |
Boehringer Ingelheim Pharma |
NEW SUBSTITUTED INDOLINONES WITH AN INHIBITING EFFECT ON VARIOUS KINASES AND CYCLIN/CDK COMPLEXES
|
KR20010101266A
(en)
|
1998-12-17 |
2001-11-14 |
프리돌린 클라우스너, 롤란드 비. 보레르 |
4-aryloxindoles as inhibitors of jnk protein kinases
|
DK1149092T3
(en)
*
|
1998-12-17 |
2004-02-23 |
Hoffmann La Roche |
4- and 5-alkynyloxindoles and 4- and 5-alkenyloxindoles
|
PT1157019E
(en)
*
|
1998-12-17 |
2003-06-30 |
Hoffmann La Roche |
4-Alkenyl (and alkynyl) oxindoles as inhibitors of cyclin-dependent kinase in particular CDK2
|
AU767138B2
(en)
|
1998-12-17 |
2003-10-30 |
F. Hoffmann-La Roche Ag |
4,5-pyrazinoxindoles as protein kinase inhibitors
|
US6153634A
(en)
|
1998-12-17 |
2000-11-28 |
Hoffmann-La Roche Inc. |
4,5-azolo-oxindoles
|
US20030119895A1
(en)
*
|
1998-12-23 |
2003-06-26 |
Pharmacia Corporation |
Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia
|
US6861442B1
(en)
*
|
1998-12-30 |
2005-03-01 |
Sugen, Inc. |
PYK2 and inflammation
|
EP1630559A3
(en)
*
|
1998-12-30 |
2006-06-07 |
Sugen, Inc. |
PYK2 (RAFTK) and inflammation
|
WO2000038519A1
(en)
*
|
1998-12-31 |
2000-07-06 |
Sugen, Inc. |
3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy
|
US6828106B2
(en)
*
|
1999-02-26 |
2004-12-07 |
Cyclacel Limited |
Methods and compositions using coiled binding partners
|
US6670144B1
(en)
*
|
1999-02-26 |
2003-12-30 |
Cyclacel, Ltd. |
Compositions and methods for monitoring the phosphorylation of natural binding partners
|
US6656696B2
(en)
*
|
1999-02-26 |
2003-12-02 |
Cyclacel |
Compositions and methods for monitoring the phosphorylation of natural binding partners
|
US6972182B1
(en)
*
|
1999-02-26 |
2005-12-06 |
Cyclacel, Ltd. |
Methods and compositions using coiled binding partners
|
US6624171B1
(en)
|
1999-03-04 |
2003-09-23 |
Smithkline Beecham Corporation |
Substituted aza-oxindole derivatives
|
US6492398B1
(en)
|
1999-03-04 |
2002-12-10 |
Smithkline Beechman Corporation |
Thiazoloindolinone compounds
|
GB9904933D0
(en)
|
1999-03-04 |
1999-04-28 |
Glaxo Group Ltd |
Compounds
|
US7064114B2
(en)
|
1999-03-19 |
2006-06-20 |
Parker Hughes Institute |
Gel-microemulsion formulations
|
AU770920C
(en)
*
|
1999-03-23 |
2004-10-07 |
Georgetown University |
Phenylalanine derivatives
|
US7226991B1
(en)
*
|
1999-03-23 |
2007-06-05 |
United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Phenylalanine derivatives
|
US6689806B1
(en)
|
1999-03-24 |
2004-02-10 |
Sugen, Inc. |
Indolinone compounds as kinase inhibitors
|
JP2002540096A
(en)
*
|
1999-03-24 |
2002-11-26 |
スージェン・インコーポレーテッド |
Indolinone compounds as kinase inhibitors
|
US6399743B1
(en)
|
1999-05-14 |
2002-06-04 |
Dept. Of Veterans Affairs |
Isolation and characterization of a rat epidermal growth factor related protein
|
US7049410B2
(en)
*
|
1999-05-14 |
2006-05-23 |
Majumdar Adhip P N |
Antibodies to a novel EGF-receptor related protein (ERRP)
|
US6762180B1
(en)
|
1999-10-13 |
2004-07-13 |
Boehringer Ingelheim Pharma Kg |
Substituted indolines which inhibit receptor tyrosine kinases
|
UA75054C2
(en)
*
|
1999-10-13 |
2006-03-15 |
Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг |
Substituted in position 6 indolinones, producing and use thereof as medicament
|
DE19949209A1
(en)
*
|
1999-10-13 |
2001-04-19 |
Boehringer Ingelheim Pharma |
5-substituted indolinones, their preparation and their use as pharmaceuticals
|
ATE362767T1
(en)
|
1999-10-22 |
2007-06-15 |
Us Gov Health & Human Serv |
INHIBITION OF CELL MOTILITY AND ANGIOGENESIS WITH GRB2 SH2-DOMAIN INHIBITORS
|
US7871981B2
(en)
*
|
1999-10-22 |
2011-01-18 |
The United States Of America As Represented By The Department Of Health And Human Services |
Inhibition of cell motility, angiogenesis, and metastasis
|
AU783082B2
(en)
*
|
1999-10-22 |
2005-09-22 |
Pharmacia & Upjohn Company |
Drosophila G protein coupled receptors, nucleic acids, and methods related to the same
|
US20030162223A1
(en)
*
|
1999-10-22 |
2003-08-28 |
Lowery David E. |
Drosophila G protein coupled receptors, nucleic acids, and methods related to the same
|
US7364866B2
(en)
*
|
1999-10-22 |
2008-04-29 |
Pharmacia & Upjohn Company |
Drosophila G protein coupled receptors, nucleic acids, and methods related to the same
|
UA74803C2
(en)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
A stable polymorph of n-(3-ethynylphenyl)-6,7-bis(2-methoxyetoxy)-4-quinazolinamine hydrochloride, a method for producing thereof (variants) and pharmaceutical use
|
AU784543B2
(en)
*
|
1999-11-16 |
2006-04-27 |
Pharmacia & Upjohn Company |
Novel G protein-coupled receptors
|
US20030082534A1
(en)
*
|
1999-11-16 |
2003-05-01 |
Peter Lind |
Novel G protein-coupled receptors
|
US8682005B2
(en)
|
1999-11-19 |
2014-03-25 |
Gentex Corporation |
Vehicle accessory microphone
|
US6878733B1
(en)
|
1999-11-24 |
2005-04-12 |
Sugen, Inc. |
Formulations for pharmaceutical agents ionizable as free acids or free bases
|
EP1103420B1
(en)
|
1999-11-24 |
2006-06-21 |
Donnelly Corporation |
Rearview mirror assembly with utility functions
|
ATE514676T1
(en)
*
|
1999-11-24 |
2011-07-15 |
Sugen Inc |
IONIZABLE INDOLINONE DERIVATIVES AND THEIR USE AS PTK LIGANDS
|
US6313310B1
(en)
|
1999-12-15 |
2001-11-06 |
Hoffmann-La Roche Inc. |
4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles
|
JP5004392B2
(en)
*
|
1999-12-22 |
2012-08-22 |
スージェン, インク. |
Method for regulating c-kit tyrosine protein kinase function using indolinone compounds
|
US6339100B1
(en)
*
|
1999-12-29 |
2002-01-15 |
The Trustees Of Columbia University In The City Of New York |
Methods for inhibiting mastocytosis
|
JP2003535038A
(en)
*
|
1999-12-30 |
2003-11-25 |
スージェン・インコーポレーテッド |
3-Heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy
|
SK287142B6
(en)
*
|
2000-02-15 |
2010-01-07 |
Sugen, Inc. |
Pyrrole substituted 2-indolinone protein kinase inhibitors, pharmacutical composition and use
|
US6620818B1
(en)
|
2000-03-01 |
2003-09-16 |
Smithkline Beecham Corporation |
Method for reducing the severity of side effects of chemotherapy and/or radiation therapy
|
MY128450A
(en)
|
2000-05-24 |
2007-02-28 |
Upjohn Co |
1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
|
CA2410509A1
(en)
*
|
2000-06-02 |
2001-12-13 |
Sugen, Inc. |
Indolinone derivatives as protein kinase/phosphatase inhibitors
|
GB0016454D0
(en)
|
2000-07-04 |
2000-08-23 |
Hoffmann La Roche |
Thienopyrrolidinones
|
US7425537B2
(en)
*
|
2000-08-22 |
2008-09-16 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
SH2 domain binding inhibitors
|
CA2419870A1
(en)
*
|
2000-08-22 |
2002-02-28 |
Yang Gao |
Sh2 domain binding inhibitors
|
US20030133972A1
(en)
*
|
2000-10-11 |
2003-07-17 |
Targesome, Inc. |
Targeted multivalent macromolecules
|
US20030129223A1
(en)
*
|
2000-10-11 |
2003-07-10 |
Targesome, Inc. |
Targeted multivalent macromolecules
|
ES2282299T3
(en)
*
|
2000-10-20 |
2007-10-16 |
EISAI R&D MANAGEMENT CO., LTD. |
AROMATIC COMPOUNDS WITH NITROGEN RINGS AS ANTICANCERIGEN AGENTS.
|
PE20020572A1
(en)
|
2000-12-06 |
2002-07-31 |
Centro Inmunologia Molecular |
PREPARATIONS TO ENHANCE THE IMMUNOGENICITY OF UNIMMUNOGENIC ANTIGENS
|
US6677368B2
(en)
*
|
2000-12-20 |
2004-01-13 |
Sugen, Inc. |
4-aryl substituted indolinones
|
AU2002249913A1
(en)
*
|
2001-01-03 |
2002-08-12 |
President And Fellows Of Harvard College |
Compounds regulating cell proliferation and differentiation
|
DZ3494A1
(en)
*
|
2001-01-05 |
2002-07-11 |
Pfizer |
INSULIN ANALOGUE GROWTH FACTOR ANTI-RECEPTOR ANTIBODIES
|
US6504034B2
(en)
|
2001-01-23 |
2003-01-07 |
Hoffmann-La Roche Inc. |
Naphthostyrils
|
US20050069976A1
(en)
*
|
2001-02-14 |
2005-03-31 |
Peter Lind |
Protein-coupled receptor
|
AR042586A1
(en)
|
2001-02-15 |
2005-06-29 |
Sugen Inc |
3- (4-AMIDOPIRROL-2-ILMETILIDEN) -2-INDOLINONE AS INHIBITORS OF PROTEIN KINASE; YOUR PHARMACEUTICAL COMPOSITIONS; A METHOD FOR THE MODULATION OF THE CATALYTIC ACTIVITY OF PROTEINQUINASE; A METHOD TO TREAT OR PREVENT AN AFFECTION RELATED TO PROTEINQUINASE
|
CZ307637B6
(en)
|
2001-02-19 |
2019-01-23 |
Novartis Ag |
40-O- (2-Hydroxyethyl) rapamycin as the only active ingredient in the treatment
|
FR2821358B1
(en)
*
|
2001-02-27 |
2006-04-07 |
Aventis Pharma Sa |
OXINDOLES INHIBITORS OF CDK-1 AND THEIR THERAPEUTIC APPLICATION
|
US7186745B2
(en)
|
2001-03-06 |
2007-03-06 |
Astrazeneca Ab |
Indolone derivatives having vascular damaging activity
|
FR2822155B1
(en)
*
|
2001-03-13 |
2003-12-12 |
Aventis Pharma Sa |
COMPOUNDS DERIVED FROM OXINDOLES AND THEIR THERAPEUTIC APPLICATION IN CANCEROLOGY
|
SE0101230L
(en)
*
|
2001-04-06 |
2002-10-07 |
Innoventus Project Ab |
New use of a tyrosine kinase inhibitor
|
WO2002081466A1
(en)
*
|
2001-04-09 |
2002-10-17 |
Sugen, Inc. |
Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
|
EP2253319A1
(en)
|
2001-05-16 |
2010-11-24 |
Novartis AG |
Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent.
|
WO2002096361A2
(en)
|
2001-05-30 |
2002-12-05 |
Sugen, Inc. |
5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
|
US6995171B2
(en)
|
2001-06-21 |
2006-02-07 |
Agouron Pharmaceuticals, Inc. |
Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents
|
PT1401413E
(en)
|
2001-06-29 |
2007-02-28 |
Ab Science |
Use of tyrosine kinase inhibitions for treating allergic diseases
|
ATE330608T1
(en)
*
|
2001-06-29 |
2006-07-15 |
Ab Science |
THE USE OF N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES
|
EP1471907B1
(en)
*
|
2001-06-29 |
2008-07-16 |
AB Science |
Use of c-kit inhibitors for treating autoimmune diseases
|
JP2005500041A
(en)
*
|
2001-06-29 |
2005-01-06 |
アブ サイエンス |
Potent, selective and non-toxic C-KIT inhibitor
|
ATE343415T1
(en)
*
|
2001-06-29 |
2006-11-15 |
Ab Science |
THE USE OF C-KIT INHIBITORS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
|
WO2003004006A2
(en)
*
|
2001-06-29 |
2003-01-16 |
Ab Science |
Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
|
DE10134196B4
(en)
|
2001-07-13 |
2005-08-18 |
Forschungszentrum Karlsruhe Gmbh Technik Und Umwelt |
A pharmaceutical composition for inhibiting the uncontrolled proliferation and / or induction of cell apoptosis
|
TWI315982B
(en)
|
2001-07-19 |
2009-10-21 |
Novartis Ag |
Combinations comprising epothilones and pharmaceutical uses thereof
|
EP3168218B1
(en)
*
|
2001-08-15 |
2018-11-14 |
Pharmacia & Upjohn Company LLC |
A crystal comprising an l-malic acid salt of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide for use as a medicament
|
AR038957A1
(en)
*
|
2001-08-15 |
2005-02-02 |
Pharmacia Corp |
COMBINATION THERAPY FOR CANCER TREATMENT
|
JP2005511506A
(en)
*
|
2001-09-20 |
2005-04-28 |
アブ サイエンス |
Use of a potent, selective and non-toxic c-kit inhibitor for treating interstitial cystitis
|
CA2461182A1
(en)
*
|
2001-09-20 |
2003-05-01 |
Ab Science |
Use of tyrosine kinase inhibitors for promoting hair growth
|
CA2461183A1
(en)
*
|
2001-09-20 |
2003-05-15 |
Ab Science |
Use of tyrosine kinase inhibitors for whitening human skin and treating melanocyte dysfunction associated diseases
|
US6559173B1
(en)
|
2001-09-27 |
2003-05-06 |
Allergan, Inc. |
3-(heteroarylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
|
CA2461812C
(en)
*
|
2001-09-27 |
2011-09-20 |
Allergan, Inc. |
3-(arylamino)methylene-1,3-dihydro-2h-indol-2-ones as kinase inhibitors
|
JP2005508953A
(en)
|
2001-10-10 |
2005-04-07 |
スージェン・インコーポレーテッド |
3- [4- (Substituted heterocyclyl) -pyrrol-2-ylmethylidene] -2-indolinone derivatives as kinase inhibitors
|
AR039067A1
(en)
*
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
ANTIBODIES FOR CD40
|
WO2003045307A2
(en)
*
|
2001-11-21 |
2003-06-05 |
Sugen, Inc. |
Pharmaceutical formulations comprising indolinone derivatives
|
US6797825B2
(en)
|
2001-12-13 |
2004-09-28 |
Abbott Laboratories |
Protein kinase inhibitors
|
US20030187026A1
(en)
|
2001-12-13 |
2003-10-02 |
Qun Li |
Kinase inhibitors
|
PE20030701A1
(en)
|
2001-12-20 |
2003-08-21 |
Schering Corp |
COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
|
IL162203A0
(en)
|
2001-12-27 |
2005-11-20 |
Theravance Inc |
Indolinone derivatives useful as protein inase inhibitors
|
DE60305446T4
(en)
*
|
2002-01-07 |
2009-07-09 |
Eisai R&D Management Co., Ltd. |
DESAZAPURINE AND ITS USE
|
AU2003216625A1
(en)
*
|
2002-02-27 |
2003-09-09 |
Ab Science |
Use of tyrosine kinase inhibitors for treating cns disorders
|
JP2005527511A
(en)
*
|
2002-03-01 |
2005-09-15 |
ファイザー インコーポレイテッド |
Indolyl-urea derivatives of thienopyridine useful as anti-angiogenic agents and methods of use thereof
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
JP4549066B2
(en)
*
|
2002-04-03 |
2010-09-22 |
アラーガン、インコーポレイテッド |
(3Z) -3- (3-Hydro-isobenzofuran-1-ylidene) -1,3-dihydro-2H-indol-2-ones as kinase inhibitors
|
US6541504B1
(en)
*
|
2002-04-03 |
2003-04-01 |
Allergan Sales, Llc |
(3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
|
CA2483594C
(en)
|
2002-05-16 |
2011-02-15 |
Novartis Ag |
Use of edg receptor binding agents in cancer
|
UA77303C2
(en)
*
|
2002-06-14 |
2006-11-15 |
Pfizer |
Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
|
WO2004012776A1
(en)
*
|
2002-08-01 |
2004-02-12 |
Pharmacia Italia S.P.A. |
Isotopically labelled indolinone derivatives and process for their preparation
|
US8450302B2
(en)
*
|
2002-08-02 |
2013-05-28 |
Ab Science |
2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
|
DK1525200T3
(en)
|
2002-08-02 |
2007-12-03 |
Ab Science |
2- (3-aminoaryl) amino-4-aryl-thiazoles for disease treatment
|
US20050032871A1
(en)
*
|
2002-09-03 |
2005-02-10 |
Sugen, Inc. |
Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors
|
US7626031B2
(en)
*
|
2002-11-15 |
2009-12-01 |
Symphony Evolution, Inc. |
Substituted 3-(diarylmethylene)indolin-2-ones and methods of their use
|
WO2004048525A2
(en)
*
|
2002-11-21 |
2004-06-10 |
Genentech, Inc. |
Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
|
US6699863B1
(en)
|
2002-11-27 |
2004-03-02 |
Allergan, Inc. |
Kinase inhibitors for the treatment of disease
|
US6747025B1
(en)
*
|
2002-11-27 |
2004-06-08 |
Allergan, Inc. |
Kinase inhibitors for the treatment of disease
|
US20040186160A1
(en)
*
|
2002-12-13 |
2004-09-23 |
Sugen, Inc. |
Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors
|
CN1747950A
(en)
*
|
2002-12-19 |
2006-03-15 |
美国辉瑞有限公司 |
2-(1h-indazole-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophthalmic diseases
|
US20040138104A1
(en)
*
|
2003-01-14 |
2004-07-15 |
The Government Of The United States Of America Represented By The Secretary, |
Peptides
|
ITRM20030074A1
(en)
*
|
2003-02-21 |
2004-08-22 |
Pharmacia Italia Spa |
SEMI-SOLID FORMULATIONS WITH IMMEDIATE RELEASE AGREEMENTS
|
AP2114A
(en)
|
2003-02-26 |
2010-03-04 |
Sugen Inc |
Aminoheteroaryl compounds as protein kinase inhibitors
|
US7157577B2
(en)
*
|
2003-03-07 |
2007-01-02 |
Sugen Inc. |
5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
|
US20040266843A1
(en)
*
|
2003-03-07 |
2004-12-30 |
Sugen, Inc. |
Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK)
|
JPWO2004080462A1
(en)
*
|
2003-03-10 |
2006-06-08 |
エーザイ株式会社 |
c-Kit kinase inhibitor
|
AU2004226586B2
(en)
*
|
2003-04-03 |
2008-12-11 |
Pfizer Inc. |
Dosage forms comprising AG013736
|
AU2004251146A1
(en)
|
2003-05-19 |
2005-01-06 |
Irm, Llc |
Immunosuppressant compounds and compositions
|
MY150088A
(en)
|
2003-05-19 |
2013-11-29 |
Irm Llc |
Immunosuppressant compounds and compositions
|
TWI476206B
(en)
|
2003-07-18 |
2015-03-11 |
Amgen Inc |
Specific binding agents to hepatocyte growth factor
|
DE10334582A1
(en)
*
|
2003-07-28 |
2005-02-24 |
Basf Ag |
Maleic anhydride production by VPO-catalyzed gas-phase oxidation of n- butane involves setting the n-butane and oxygen content levels in a pressure- controlled feed to reduce risk of explosions
|
HN2004000285A
(en)
*
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTIBODIES DIRECTED TO c-MET
|
CA2534509A1
(en)
*
|
2003-08-06 |
2005-02-24 |
Sugen, Inc. |
Geometrically restricted 3-cyclopentylidene-1,3-dihydroindol-2-ones as potent protein kinase inhibitors
|
EP1653934B1
(en)
*
|
2003-08-15 |
2008-05-14 |
AB Science |
Use of c-kit inhibitors for treating type ii diabetes
|
BRPI0414011A
(en)
*
|
2003-08-29 |
2006-10-24 |
Pfizer |
naphthalencarboxamides and their derivatives useful as new antiangiogenic agents
|
DE602004017479D1
(en)
*
|
2003-08-29 |
2008-12-11 |
Pfizer |
THIENOPYRIDINPHENYLACETAMIDES SUITED AS NEW ANTIANGIOGENIC AGENTS AND DERIVATIVES THEREOF
|
AR045563A1
(en)
*
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
ANTIBODIES DIRECTED TO M-CSF
|
US20050119163A1
(en)
|
2003-09-18 |
2005-06-02 |
The Government Of The United States Of America, As Represented By The Secretary, |
SH2 domain binding inhibitors
|
CA2542909C
(en)
*
|
2003-10-23 |
2012-07-10 |
Ab Science |
2-aminoaryloxazole compounds as tyrosine kinase inhibitors
|
RU2006117635A
(en)
*
|
2003-10-24 |
2007-12-10 |
Шеринг Акциенгезельшафт (De) |
DERIVATIVES OF INDOLINON AND THEIR APPLICATION FOR TREATMENT OF PATHOLOGICAL CONDITIONS SUCH AS A MALIGNANT NEW FORMATION
|
CN100450998C
(en)
*
|
2003-11-11 |
2009-01-14 |
卫材R&D管理有限公司 |
Urea derivative and process for producing the same
|
EP1689721B1
(en)
*
|
2003-11-26 |
2010-07-14 |
Pfizer Products Inc. |
Aminopyrazole derivatives as gsk-3 inhibitors
|
EP1696906A1
(en)
*
|
2003-12-16 |
2006-09-06 |
Leo Pharma A/S |
Novel therapeutic use of indolinone derivatives
|
SG141459A1
(en)
*
|
2003-12-23 |
2008-04-28 |
Pfizer |
Novel quinoline derivatives
|
US7816137B2
(en)
|
2004-01-30 |
2010-10-19 |
Lifecord Inc. |
Method for isolating and culturing multipotent progenitor cells from umbilical cord blood
|
CA2556025A1
(en)
*
|
2004-02-23 |
2005-09-09 |
Sugen, Inc. |
Method of treating abnormal cell growth using c-met and m-tor inhibitors
|
DE102004012070A1
(en)
*
|
2004-03-12 |
2005-09-29 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
New cycloalkyl-containing 5-acylindolinones, their preparation and their use as medicaments
|
WO2005094830A1
(en)
*
|
2004-03-30 |
2005-10-13 |
Pfizer Products Inc. |
Combinations of signal transduction inhibitors
|
US8512738B2
(en)
|
2004-04-30 |
2013-08-20 |
Allergan, Inc. |
Biodegradable intravitreal tyrosine kinase implants
|
US8455656B2
(en)
|
2004-04-30 |
2013-06-04 |
Allergan, Inc. |
Kinase inhibitors
|
US7771742B2
(en)
|
2004-04-30 |
2010-08-10 |
Allergan, Inc. |
Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
|
GB0512324D0
(en)
|
2005-06-16 |
2005-07-27 |
Novartis Ag |
Organic compounds
|
WO2006002422A2
(en)
|
2004-06-24 |
2006-01-05 |
Novartis Vaccines And Diagnostics Inc. |
Compounds for immunopotentiation
|
MX2007000610A
(en)
*
|
2004-07-16 |
2007-03-07 |
Pfizer Prod Inc |
Combination treatment for non-hematologic malignancies using an anti-ogf-1r antibody.
|
EP1784396B8
(en)
*
|
2004-08-26 |
2011-04-20 |
Pfizer Inc. |
Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
|
GEP20104906B
(en)
|
2004-08-26 |
2010-02-25 |
Pfizer |
Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
|
WO2006021886A1
(en)
*
|
2004-08-26 |
2006-03-02 |
Pfizer Inc. |
Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
|
US8772269B2
(en)
*
|
2004-09-13 |
2014-07-08 |
Eisai R&D Management Co., Ltd. |
Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
|
EP2364699A1
(en)
|
2004-09-13 |
2011-09-14 |
Eisai R&D Management Co., Ltd. |
Joint use of sulfonamide based compound with angiogenesis inhibitor
|
JP4834553B2
(en)
*
|
2004-09-17 |
2011-12-14 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
Pharmaceutical composition
|
GB0423043D0
(en)
*
|
2004-10-16 |
2004-11-17 |
Astrazeneca Ab |
Compounds
|
US20060107555A1
(en)
*
|
2004-11-09 |
2006-05-25 |
Curtis Marc D |
Universal snow plow adapter
|
JP2008524165A
(en)
*
|
2004-12-17 |
2008-07-10 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Indolinone and its use as an antiproliferative agent
|
PE20060777A1
(en)
*
|
2004-12-24 |
2006-10-06 |
Boehringer Ingelheim Int |
INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
|
SG176463A1
(en)
|
2005-02-22 |
2011-12-29 |
Univ Michigan |
Small molecule inhibitors of mdm2 and uses thereof
|
WO2006105488A2
(en)
|
2005-03-31 |
2006-10-05 |
Agensys, Inc. |
Antibodies and related molecules that bind to 161p2f10b proteins
|
KR20080019578A
(en)
*
|
2005-04-04 |
2008-03-04 |
에이비 사이언스 |
Substituted oxazole derivatives and their use as tyrosine kinase inhibitors
|
MX2007013304A
(en)
|
2005-04-26 |
2007-12-13 |
Pfizer |
P-cadherin antibodies.
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
AU2006268174A1
(en)
|
2005-07-13 |
2007-01-18 |
Allergan, Inc. |
Kinase inhibitors
|
US7749530B2
(en)
|
2005-07-13 |
2010-07-06 |
Allergan, Inc. |
Kinase inhibitors
|
CA2602389A1
(en)
*
|
2005-07-13 |
2007-01-18 |
Allergan, Inc. |
Kinase inhibitors
|
US7309787B2
(en)
*
|
2005-07-13 |
2007-12-18 |
Allergan, Inc. |
Kinase inhibitors
|
EP1925941B1
(en)
*
|
2005-08-01 |
2012-11-28 |
Eisai R&D Management Co., Ltd. |
Method for prediction of the efficacy of vascularization inhibitor
|
JP4989476B2
(en)
|
2005-08-02 |
2012-08-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
Methods for assaying the effects of angiogenesis inhibitors
|
EP1938842A4
(en)
*
|
2005-09-01 |
2013-01-09 |
Eisai R&D Man Co Ltd |
Method for preparation of pharmaceutical composition having improved disintegradability
|
PT2447283E
(en)
|
2005-09-07 |
2015-10-08 |
Pfizer |
Human monoclonal antibodies to activin receptor-like kinase-1 (alk-1)
|
JP5055284B2
(en)
|
2005-09-20 |
2012-10-24 |
オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー |
Biological markers for predicting anti-cancer responses to insulin-like growth factor-1 receptor kinase inhibitors
|
CA2623034A1
(en)
|
2005-09-27 |
2007-04-05 |
Novartis Ag |
Carboxyamine compounds and their use in the treatment of hdac dependent diseases
|
CN101316590B
(en)
|
2005-11-07 |
2011-08-03 |
卫材R&D管理有限公司 |
Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
|
AU2006314444C1
(en)
|
2005-11-21 |
2018-01-04 |
Novartis Ag |
Neuroendocrine tumor treatment using mTOR inhibitors
|
US20090247576A1
(en)
*
|
2005-11-22 |
2009-10-01 |
Eisai R & D Management Co., Ltd. |
Anti-tumor agent for multiple myeloma
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
PI-3 Kinase inhibitors and methods of their use
|
US8367664B2
(en)
|
2006-01-24 |
2013-02-05 |
Allergan, Inc. |
Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors
|
PE20070978A1
(en)
*
|
2006-02-14 |
2007-11-15 |
Novartis Ag |
HETEROCICLIC COMPOUNDS AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASES (PI3Ks)
|
EP2001880A2
(en)
|
2006-03-07 |
2008-12-17 |
Array Biopharma, Inc. |
Heterobicyclic pyrazole compounds and methods of use
|
US7977351B2
(en)
*
|
2006-03-22 |
2011-07-12 |
Allergan, Inc. |
Heteroaryl dihydroindolones as kinase inhibitors
|
MX2008012715A
(en)
|
2006-04-05 |
2008-10-14 |
Novartis Ag |
Combinations of therapeutic agents for treating cancer.
|
AR060358A1
(en)
*
|
2006-04-06 |
2008-06-11 |
Novartis Vaccines & Diagnostic |
QUINAZOLINS FOR THE INHIBITION OF PDK 1
|
KR20080110912A
(en)
|
2006-04-19 |
2008-12-19 |
노파르티스 아게 |
Indazole compounds and methods for inhibition of cdc7
|
MX2008014292A
(en)
|
2006-05-09 |
2008-11-18 |
Novartis Ag |
Combination comprising an iron chelator and an anti-neoplastic agent and use thereof.
|
EA200802058A1
(en)
|
2006-05-09 |
2009-06-30 |
Пфайзер Продактс Инк. |
DERIVATIVES OF CYCLO-ALKYLAMINO ACIDS AND THEIR PHARMACEUTICAL COMPOSITIONS
|
RU2448708C3
(en)
*
|
2006-05-18 |
2017-09-28 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
ANTI-TUMOR MEANS AGAINST THYROID CANCER CANCER
|
US20110053931A1
(en)
*
|
2006-06-08 |
2011-03-03 |
John Gaudino |
Quinoline compounds and methods of use
|
GB0612721D0
(en)
|
2006-06-27 |
2006-08-09 |
Novartis Ag |
Organic compounds
|
JPWO2008001956A1
(en)
*
|
2006-06-29 |
2009-12-03 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
Liver fibrosis treatment
|
US8217177B2
(en)
|
2006-07-14 |
2012-07-10 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
PE20080403A1
(en)
|
2006-07-14 |
2008-04-25 |
Amgen Inc |
FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE
|
US8246966B2
(en)
|
2006-08-07 |
2012-08-21 |
University Of Georgia Research Foundation, Inc. |
Trypanosome microsome system and uses thereof
|
WO2008022013A1
(en)
*
|
2006-08-11 |
2008-02-21 |
Allergan, Inc. |
Kinase inhibitors
|
JP5368096B2
(en)
*
|
2006-08-28 |
2013-12-18 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
Anti-tumor agent for undifferentiated gastric cancer
|
US20090286779A1
(en)
|
2006-09-29 |
2009-11-19 |
Novartis Ag |
Pyrazolopyrimidines as lipid kinase inhibitors
|
JP5518479B2
(en)
*
|
2006-10-25 |
2014-06-11 |
ザ ロックフェラー ユニヴァーシティ |
Methods and compositions for the treatment of Aβ related disorders
|
EP2099757B1
(en)
|
2006-11-16 |
2014-06-25 |
Allergan, Inc. |
Sulfoximines as kinase inhibitors
|
US8558002B2
(en)
|
2006-11-16 |
2013-10-15 |
Allergan, Inc. |
Sulfoximines as kinase inhibitors
|
US8143410B2
(en)
|
2006-11-16 |
2012-03-27 |
Allergan, Inc. |
Kinase inhibitors
|
US8338433B2
(en)
*
|
2006-11-22 |
2012-12-25 |
University Of Georgia Research Foundation, Inc. |
Tyrosine kinase inhibitors as anti-kinetoplastid agents
|
WO2008066498A1
(en)
*
|
2006-12-01 |
2008-06-05 |
Agency For Science, Technology And Research |
Cancer-related protein kinases
|
KR101445892B1
(en)
*
|
2007-01-29 |
2014-09-29 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
Composition for treatment of undifferentiated-type of gastric cancer
|
US9187485B2
(en)
*
|
2007-02-02 |
2015-11-17 |
Baylor College Of Medicine |
Methods and compositions for the treatment of cancer and related hyperproliferative disorders
|
RU2009134223A
(en)
|
2007-02-15 |
2011-03-20 |
Новартис АГ (CH) |
COMBINATION OF LBH589 WITH OTHER THERAPEUTIC MEDICINES FOR THE TREATMENT OF CANCER
|
US8314087B2
(en)
|
2007-02-16 |
2012-11-20 |
Amgen Inc. |
Nitrogen-containing heterocyclyl ketones and methods of use
|
US20100255004A1
(en)
*
|
2007-04-13 |
2010-10-07 |
Dana Farber Cancer Institute |
Receptor tyrosine kinase profiling
|
ES2529790T3
(en)
|
2007-04-13 |
2015-02-25 |
Dana-Farber Cancer Institute, Inc. |
Methods of treating cancer resistant to therapeutic agents of ERBB
|
US7825143B2
(en)
|
2007-07-10 |
2010-11-02 |
Montana State University - Billings |
Method for controlling the yeast-to-filamentous growth transition in fungi
|
EA201591355A1
(en)
|
2007-08-21 |
2016-04-29 |
Амген Инк. |
ANTIGEN-BINDING PROTEINS, CONNECTING c-fms of the PERSON
|
CA2704000C
(en)
|
2007-11-09 |
2016-12-13 |
Eisai R&D Management Co., Ltd. |
Combination of anti-angiogenic substance and anti-tumor platinum complex
|
CA2710122A1
(en)
|
2007-12-20 |
2009-07-02 |
Novartis Ag |
Thiazole derivatives used as pi 3 kinase inhibitors
|
EP2235004A4
(en)
|
2007-12-21 |
2011-05-04 |
Univ Health Network |
Indazolyl, benzimidazolyl, benzotriazolyl substituted indolmone derivatives as kinase inhibitors useful in the treatment of cancer
|
WO2009092052A2
(en)
*
|
2008-01-18 |
2009-07-23 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for treating polyps
|
US20100324087A1
(en)
*
|
2008-01-29 |
2010-12-23 |
Eisai R&D Management Co., Ltd. |
Combined use of angiogenesis inhibitor and taxane
|
WO2009151683A2
(en)
|
2008-03-12 |
2009-12-17 |
Link Medicine Corporation |
Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
|
EA019033B1
(en)
|
2008-03-26 |
2013-12-30 |
Новартис Аг |
Hydroxamate-based inhibitors of deacetylases b
|
CA2758016A1
(en)
*
|
2008-06-05 |
2009-12-10 |
Novotyr Therapeutics Ltd. |
Novel modulators of protein kinase signaling
|
WO2010002933A1
(en)
*
|
2008-06-30 |
2010-01-07 |
Cylene Pharmaceuticals, Inc. |
Oxindole compounds
|
US20100029491A1
(en)
*
|
2008-07-11 |
2010-02-04 |
Maike Schmidt |
Methods and compositions for diagnostic use for tumor treatment
|
WO2010011349A2
(en)
*
|
2008-07-25 |
2010-01-28 |
Supergen, Inc. |
Pyrimidine-2,4-diamine jak2 kinase inhibiting anti-inflammation use
|
WO2010017541A2
(en)
*
|
2008-08-08 |
2010-02-11 |
The Johns Hopkins University |
Compositions and methods for treatment of neurodegenerative disease
|
WO2010025414A2
(en)
*
|
2008-08-29 |
2010-03-04 |
Genentech, Inc. |
Diagnostics and treatments for vegf-independent tumors
|
US20110269812A1
(en)
*
|
2008-10-14 |
2011-11-03 |
Agency For Science, Technology And Research |
Novel benzylidene-indolinone and their medical and diagnostic uses
|
JP5836125B2
(en)
|
2008-10-16 |
2015-12-24 |
ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション |
Fully human antibodies against high molecular weight melanoma-related antigens and uses thereof
|
EP2344161B1
(en)
|
2008-10-16 |
2018-12-19 |
Celator Pharmaceuticals, Inc. |
Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab
|
BRPI0920927A2
(en)
|
2008-11-13 |
2019-09-24 |
Link Medicine Corp |
azaquinolinone derivatives and uses thereof
|
US20100222371A1
(en)
*
|
2008-11-20 |
2010-09-02 |
Children's Medical Center Corporation |
Prevention of surgical adhesions
|
CN103204794A
(en)
|
2008-12-18 |
2013-07-17 |
诺瓦提斯公司 |
New Salts
|
RS53041B
(en)
|
2008-12-18 |
2014-04-30 |
Novartis Ag |
Hemifumarate salt of 1-[4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidine-3-carboxylic acid
|
US8173634B2
(en)
|
2008-12-18 |
2012-05-08 |
Novartis Ag |
Polymorphic form of 1-(4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl}-2-ethyl-benzyl)-azetidine-3-carboxylic
|
US20110281917A1
(en)
|
2009-01-29 |
2011-11-17 |
Darrin Stuart |
Substituted Benzimidazoles for the Treatment of Astrocytomas
|
EP2393814A1
(en)
*
|
2009-02-09 |
2011-12-14 |
SuperGen, Inc. |
Pyrrolopyrimidinyl axl kinase inhibitors
|
WO2010099139A2
(en)
|
2009-02-25 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Combination anti-cancer therapy
|
WO2010099137A2
(en)
|
2009-02-26 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
In situ methods for monitoring the emt status of tumor cells in vivo
|
WO2010099363A1
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
TW201035088A
(en)
|
2009-02-27 |
2010-10-01 |
Supergen Inc |
Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
JP2012519282A
(en)
|
2009-02-27 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
Methods for identifying mesenchymal tumor cells or agents that inhibit their production
|
WO2010115279A1
(en)
|
2009-04-06 |
2010-10-14 |
University Health Network |
Kinase inhibitors and method of treating cancer with same
|
CA2761243A1
(en)
|
2009-05-12 |
2010-11-18 |
Taiho Pharmaceutical Co., Ltd. |
Anti-tumor agent containing tegafur-gimeracil-oteracil potassium combination drug and oxaliplatin
|
CA2765983C
(en)
|
2009-06-26 |
2017-11-14 |
Novartis Ag |
1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
AU2010273585B2
(en)
|
2009-07-13 |
2015-04-23 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of cancer
|
JP2013500991A
(en)
|
2009-07-31 |
2013-01-10 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
mTOR inhibitor and angiogenesis inhibitor combination therapy
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
EA201200260A1
(en)
|
2009-08-12 |
2012-09-28 |
Новартис Аг |
HETEROCYCLIC HYDRAZONES AND THEIR APPLICATION FOR THE TREATMENT OF CANCER AND INFLAMMATION
|
GEP201706639B
(en)
|
2009-08-17 |
2017-03-27 |
Intellikine Llc |
Heterocyclic compounds and uses thereof
|
IN2012DN01453A
(en)
|
2009-08-20 |
2015-06-05 |
Novartis Ag |
|
WO2011023677A1
(en)
|
2009-08-26 |
2011-03-03 |
Novartis Ag |
Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
|
JP2013503846A
(en)
|
2009-09-01 |
2013-02-04 |
ファイザー・インク |
Benzimidazole derivatives
|
US9340555B2
(en)
|
2009-09-03 |
2016-05-17 |
Allergan, Inc. |
Compounds as tyrosine kinase modulators
|
RU2012112151A
(en)
|
2009-09-03 |
2013-10-10 |
Аллерган, Инк. |
COMPOUNDS AS TYROSINKINASE MODULATORS
|
MX2012002997A
(en)
|
2009-09-10 |
2012-08-01 |
Novartis Ag |
Ether derivatives of bicyclic heteroaryls.
|
CA2773662A1
(en)
|
2009-09-11 |
2011-03-17 |
Genentech, Inc. |
Method to identify a patient with an increased likelihood of responding to an anti-cancer agent
|
WO2011033006A1
(en)
|
2009-09-17 |
2011-03-24 |
F. Hoffmann-La Roche Ag |
Methods and compositions for diagnostics use in cancer patients
|
EA201200651A1
(en)
|
2009-11-04 |
2012-12-28 |
Новартис Аг |
HETEROCYCLIC SULPHONAMIDE DERIVATIVES APPLICABLE AS MEK INHIBITORS
|
US20120289501A1
(en)
|
2009-11-25 |
2012-11-15 |
Novartis Ag |
Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
|
WO2011070030A1
(en)
|
2009-12-08 |
2011-06-16 |
Novartis Ag |
Heterocyclic sulfonamide derivatives
|
AU2012265844A1
(en)
|
2009-12-08 |
2013-05-02 |
Novartis Ag |
Heterocyclic sulfonamide derivatives
|
WO2011073521A1
(en)
|
2009-12-15 |
2011-06-23 |
Petri Salven |
Methods for enriching adult-derived endothelial progenitor cells and uses thereof
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
CU24130B1
(en)
|
2009-12-22 |
2015-09-29 |
Novartis Ag |
ISOQUINOLINONES AND REPLACED QUINAZOLINONES
|
RS55487B1
(en)
|
2010-02-12 |
2017-04-28 |
Pfizer |
Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
|
AU2011223643A1
(en)
|
2010-03-03 |
2012-06-28 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
US20110217309A1
(en)
|
2010-03-03 |
2011-09-08 |
Buck Elizabeth A |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
US8921545B2
(en)
|
2010-04-06 |
2014-12-30 |
University Health Network |
Synthesis of chiral 2-(1H-indazol-6-yl)-spiro[cyclopropane-1,3′-indolin]-2′-ones
|
WO2011153224A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of cancer
|
WO2011159835A1
(en)
|
2010-06-16 |
2011-12-22 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Antibodies to endoplasmin and their use
|
CN102947274A
(en)
|
2010-06-17 |
2013-02-27 |
诺瓦提斯公司 |
Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
|
CN102947275A
(en)
|
2010-06-17 |
2013-02-27 |
诺瓦提斯公司 |
Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
|
US9012458B2
(en)
|
2010-06-25 |
2015-04-21 |
Eisai R&D Management Co., Ltd. |
Antitumor agent using compounds having kinase inhibitory effect in combination
|
KR20130126576A
(en)
|
2010-07-19 |
2013-11-20 |
에프. 호프만-라 로슈 아게 |
Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
|
KR20130055647A
(en)
|
2010-07-19 |
2013-05-28 |
에프. 호프만-라 로슈 아게 |
Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
|
US20130177500A1
(en)
|
2010-07-23 |
2013-07-11 |
Trustee Of Boston University |
Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
|
CN101912363A
(en)
*
|
2010-07-29 |
2010-12-15 |
蔡海德 |
Dissolving ultrafiltration-spray drying-molecule dispersion coating-hydration palletizing-freeze drying method for preparing liposome combination medicine
|
AR082418A1
(en)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
CRYSTAL FORMS OF 1- (4-METHYL-5- [2- (2,2,2-TRIFLUORO-1,1-DIMETHYL-Ethyl) -PIRIDIN-4-IL] -TIAZOL-2-IL) -AMIDE OF 2 -AMIDA OF THE ACID (S) -PIRROLIDIN-1,2-DICARBOXILICO
|
WO2012027716A1
(en)
|
2010-08-27 |
2012-03-01 |
Collabrx, Inc. |
Method to treat melanoma in braf inhibitor-resistant subjects
|
JP2013537210A
(en)
|
2010-09-16 |
2013-09-30 |
ノバルティス アーゲー |
17α-hydroxylase / C17,20-lyase inhibitor
|
WO2012042421A1
(en)
|
2010-09-29 |
2012-04-05 |
Pfizer Inc. |
Method of treating abnormal cell growth
|
WO2012052948A1
(en)
|
2010-10-20 |
2012-04-26 |
Pfizer Inc. |
Pyridine- 2- derivatives as smoothened receptor modulators
|
ES2611885T3
(en)
|
2011-01-31 |
2017-05-11 |
Novartis Ag |
Novel Heterocyclic Derivatives
|
EP2673277A1
(en)
|
2011-02-10 |
2013-12-18 |
Novartis AG |
[1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
WO2012116040A1
(en)
|
2011-02-22 |
2012-08-30 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
WO2012116237A2
(en)
|
2011-02-23 |
2012-08-30 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
CN103492390A
(en)
|
2011-03-08 |
2014-01-01 |
诺瓦提斯公司 |
Fluorophenyl bicyclic heteroaryl compounds
|
ES2620521T3
(en)
|
2011-03-23 |
2017-06-28 |
Amgen Inc. |
Dual condensed tricyclic inhibitors of CDK 4/6 and FLT3
|
US9150644B2
(en)
|
2011-04-12 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
|
CA2828946C
(en)
|
2011-04-18 |
2016-06-21 |
Eisai R&D Management Co., Ltd. |
Therapeutic agent for tumor
|
DK2699598T3
(en)
|
2011-04-19 |
2019-04-23 |
Pfizer |
COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER
|
US9896730B2
(en)
|
2011-04-25 |
2018-02-20 |
OSI Pharmaceuticals, LLC |
Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
|
CN103649073B
(en)
|
2011-04-28 |
2016-04-13 |
诺瓦提斯公司 |
17 α-hydroxylase/C 17,20-lyase inhibitor
|
ES2841809T3
(en)
|
2011-06-03 |
2021-07-09 |
Eisai R&D Man Co Ltd |
Biomarkers to predict and evaluate the degree of response of subjects with thyroid and kidney cancer to lenvatinib compounds
|
US8859586B2
(en)
|
2011-06-20 |
2014-10-14 |
Novartis Ag |
Cyclohexyl isoquinolinone compounds
|
EP2721008B1
(en)
|
2011-06-20 |
2015-04-29 |
Novartis AG |
Hydroxy substituted isoquinolinone derivatives as p53 (mdm2 or mdm4) inhibitors
|
ES2671748T3
(en)
|
2011-07-21 |
2018-06-08 |
Tolero Pharmaceuticals, Inc. |
Heterocyclic protein kinase inhibitors
|
SG187375A1
(en)
|
2011-08-04 |
2013-02-28 |
Univ Singapore |
Benzylidene-indolinone compounds and their medical uses
|
WO2013025939A2
(en)
|
2011-08-16 |
2013-02-21 |
Indiana University Research And Technology Corporation |
Compounds and methods for treating cancer by inhibiting the urokinase receptor
|
WO2013038362A1
(en)
|
2011-09-15 |
2013-03-21 |
Novartis Ag |
6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
|
CN103814030A
(en)
|
2011-09-22 |
2014-05-21 |
辉瑞大药厂 |
Pyrrolopyrimidine and purine derivatives
|
EP2764025B1
(en)
|
2011-10-04 |
2017-11-29 |
IGEM Therapeutics Limited |
Ige-antibodies against hmw-maa
|
PL2771342T3
(en)
|
2011-10-28 |
2016-11-30 |
|
Purine derivatives and their use in the treatment of disease
|
RU2014114015A
(en)
|
2011-11-08 |
2015-12-20 |
Пфайзер Инк. |
METHODS FOR TREATING INFLAMMATORY DISORDERS USING ANTIBODIES AGAINST M-CSF
|
JP5992054B2
(en)
|
2011-11-29 |
2016-09-14 |
ノバルティス アーゲー |
Pyrazolopyrrolidine compound
|
EA201491259A1
(en)
|
2011-12-23 |
2014-11-28 |
Новартис Аг |
COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE INTERACTION OF BCL2 WITH BOND PARTNERS
|
AU2012355624A1
(en)
|
2011-12-23 |
2014-07-17 |
Novartis Ag |
Compounds for inhibiting the interaction of BCL2 with binding partners
|
EA201491264A1
(en)
|
2011-12-23 |
2014-11-28 |
Новартис Аг |
COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL-2 WITH PARTNERS ON BINDING
|
CA2859862A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
KR20140107575A
(en)
|
2011-12-23 |
2014-09-04 |
노파르티스 아게 |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
CN102491932A
(en)
*
|
2011-12-26 |
2012-06-13 |
天津科技大学 |
3-indoline ketone derivative, and preparation method and application thereof
|
UY34591A
(en)
|
2012-01-26 |
2013-09-02 |
Novartis Ag |
IMIDAZOPIRROLIDINONA COMPOUNDS
|
AR090263A1
(en)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME
|
ES2894830T3
(en)
|
2012-04-03 |
2022-02-16 |
Novartis Ag |
Combination products with tyrosine kinase inhibitors and their use
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
SG10201608469RA
(en)
|
2012-05-16 |
2016-11-29 |
Novartis Ag |
Dosage regimen for a pi-3 kinase inhibitor
|
CN104321325B
(en)
|
2012-05-24 |
2016-11-16 |
诺华股份有限公司 |
Pyrrolopyrrole alkanone compound
|
DK2909181T3
(en)
|
2012-10-16 |
2017-11-20 |
Tolero Pharmaceuticals Inc |
PKM2 modulators and methods for their use
|
US9260426B2
(en)
|
2012-12-14 |
2016-02-16 |
Arrien Pharmaceuticals Llc |
Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
|
MX2015004979A
(en)
|
2012-12-21 |
2015-07-17 |
Eisai R&D Man Co Ltd |
Amorphous form of quinoline derivative, and method for producing same.
|
WO2014115080A1
(en)
|
2013-01-22 |
2014-07-31 |
Novartis Ag |
Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
|
WO2014115077A1
(en)
|
2013-01-22 |
2014-07-31 |
Novartis Ag |
Substituted purinone compounds
|
DK2970205T3
(en)
|
2013-03-14 |
2019-07-29 |
Tolero Pharmaceuticals Inc |
JAK2 and ALK2 inhibitors and methods for their use
|
WO2014151147A1
(en)
|
2013-03-15 |
2014-09-25 |
Intellikine, Llc |
Combination of kinase inhibitors and uses thereof
|
WO2014155268A2
(en)
|
2013-03-25 |
2014-10-02 |
Novartis Ag |
Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
|
US9206188B2
(en)
|
2013-04-18 |
2015-12-08 |
Arrien Pharmaceuticals Llc |
Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
|
AU2014266223B2
(en)
|
2013-05-14 |
2020-06-25 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
EP3021944B1
(en)
|
2013-07-14 |
2018-12-19 |
Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. |
Igf-1r signaling pathway inhibitors useful in the treatment of neurodegenerative diseases
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
WO2015051304A1
(en)
|
2013-10-04 |
2015-04-09 |
Aptose Biosciences Inc. |
Compositions, biomarkers and their use in treatment of cancer
|
KR102195494B1
(en)
|
2013-10-18 |
2020-12-28 |
유니버시티 헬스 네트워크 |
Treatment for pancreatic cancer
|
US20150141438A1
(en)
*
|
2013-11-15 |
2015-05-21 |
Pharmacyclics, Inc. |
Methods for delaying or preventing the onset of type 1 diabetes
|
UA115388C2
(en)
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-substituted purine derivatives and their use in the treatment of proliferative disorders
|
WO2015084804A1
(en)
|
2013-12-03 |
2015-06-11 |
Novartis Ag |
Combination of mdm2 inhibitor and braf inhibitor and their use
|
CN105979947A
(en)
|
2013-12-06 |
2016-09-28 |
诺华股份有限公司 |
Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
|
RU2016132574A
(en)
|
2014-01-09 |
2018-02-12 |
Интра-Селлулар Терапиз, Инк. |
ORGANIC COMPOUNDS
|
EP3122900A1
(en)
|
2014-03-24 |
2017-02-01 |
F. Hoffmann-La Roche AG |
Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
|
CN106536753B
(en)
|
2014-04-04 |
2020-07-21 |
中美冠科生物技术(太仓)有限公司 |
Methods for determining responsiveness to MEK/ERK inhibitors
|
WO2015155624A1
(en)
|
2014-04-10 |
2015-10-15 |
Pfizer Inc. |
Dihydropyrrolopyrimidine derivatives
|
EP3137460B1
(en)
|
2014-04-30 |
2019-10-23 |
Pfizer Inc |
Cycloalkyl-linked diheterocycle derivatives
|
WO2016001789A1
(en)
|
2014-06-30 |
2016-01-07 |
Pfizer Inc. |
Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
|
ES2831416T3
(en)
|
2014-07-31 |
2021-06-08 |
Novartis Ag |
Combination therapy of a MET inhibitor and an EGFR inhibitor
|
ES2848857T3
(en)
|
2014-07-31 |
2021-08-12 |
Us Gov Health & Human Services |
Human monoclonal antibodies against EphA4 and their use
|
ES2926687T3
(en)
|
2014-08-28 |
2022-10-27 |
Eisai R&D Man Co Ltd |
Highly pure quinoline derivative and method for its production
|
CN105481751A
(en)
*
|
2014-09-16 |
2016-04-13 |
中国科学院海洋研究所 |
2-indolinone derivatives, preparation and applications thereof
|
CN104326964A
(en)
*
|
2014-09-16 |
2015-02-04 |
中国科学院海洋研究所 |
Fluoro2-indolone derivatives and preparation and application thereof
|
ES2746839T3
(en)
|
2014-12-18 |
2020-03-09 |
Pfizer |
Pyrimidine and triazine derivatives and their use as AXL inhibitors
|
CN112494653A
(en)
|
2015-02-05 |
2021-03-16 |
特尔诺沃有限公司 |
Combination of IRS/STAT3 dual modulators and anticancer agents for the treatment of cancer
|
HUE064614T2
(en)
|
2015-02-25 |
2024-04-28 |
Eisai R&D Man Co Ltd |
Method for suppressing bitterness of quinoline derivative
|
KR102662228B1
(en)
|
2015-03-04 |
2024-05-02 |
머크 샤프 앤드 돔 코포레이션 |
Combination of PD-1 antagonists and VEGFR/FGFR/RET tyrosine kinase inhibitors to treat cancer
|
RU2717829C2
(en)
|
2015-04-20 |
2020-03-26 |
Толеро Фармасьютикалз, Инк. |
Prediction of response to alvicidib by analysis of mitochondrion profile
|
WO2016178876A2
(en)
|
2015-05-01 |
2016-11-10 |
Cocrystal Pharma, Inc. |
Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
|
ES2739749T3
(en)
|
2015-05-18 |
2020-02-03 |
Tolero Pharmaceuticals Inc |
Alvocidib prodrugs that have increased bioavailability
|
AU2016279474B2
(en)
|
2015-06-16 |
2021-09-09 |
Eisai R&D Management Co., Ltd. |
Anticancer agent
|
WO2017009751A1
(en)
|
2015-07-15 |
2017-01-19 |
Pfizer Inc. |
Pyrimidine derivatives
|
WO2017024073A1
(en)
|
2015-08-03 |
2017-02-09 |
Tolero Pharmaceuticals, Inc. |
Combination therapies for treatment of cancer
|
EP3370719A1
(en)
|
2015-11-02 |
2018-09-12 |
Novartis AG |
Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
|
EA201891304A1
(en)
|
2015-12-03 |
2019-01-31 |
Агиос Фармасьютикалс, Инк. |
MAT2A INHIBITORS FOR THE TREATMENT OF MTAP-null MALIGNANT TUMORS
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
WO2018094275A1
(en)
|
2016-11-18 |
2018-05-24 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
MX2019007332A
(en)
|
2016-12-19 |
2019-11-18 |
Tolero Pharmaceuticals Inc |
Profiling peptides and methods for sensitivity profiling.
|
LT3558955T
(en)
|
2016-12-22 |
2021-11-10 |
Amgen Inc. |
Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
|
JOP20190272A1
(en)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
Kras g12c inhibitors and methods of using the same
|
TWI731264B
(en)
|
2017-09-08 |
2021-06-21 |
美商安進公司 |
Inhibitors of kras g12c and methods of using the same
|
JP7196160B2
(en)
|
2017-09-12 |
2022-12-26 |
スミトモ ファーマ オンコロジー, インコーポレイテッド |
Treatment Regimens for Cancers Insensitive to BCL-2 Inhibitors Using the MCL-1 Inhibitor Albocidib
|
WO2019075367A1
(en)
|
2017-10-13 |
2019-04-18 |
Tolero Pharmaceuticals, Inc. |
Pkm2 activators in combination with reactive oxygen species for treatment of cancer
|
CA3079076A1
(en)
|
2017-10-18 |
2019-04-25 |
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus |
Methods and compounds for improved immune cell therapy
|
EP3730483B1
(en)
|
2017-12-21 |
2023-08-30 |
Hefei Institutes of Physical Science, Chinese Academy of Sciences |
Class of pyrimidine derivative kinase inhibitors
|
MX2020011582A
(en)
|
2018-05-04 |
2020-11-24 |
Amgen Inc |
Kras g12c inhibitors and methods of using the same.
|
JP7266043B2
(en)
|
2018-05-04 |
2023-04-27 |
アムジエン・インコーポレーテツド |
KRas G12C inhibitors and methods of using them
|
JP7361720B2
(en)
|
2018-05-10 |
2023-10-16 |
アムジエン・インコーポレーテツド |
KRAS G12C inhibitors for the treatment of cancer
|
EP3802535B1
(en)
|
2018-06-01 |
2022-12-14 |
Amgen, Inc |
Kras g12c inhibitors and methods of using the same
|
AU2019284472B2
(en)
|
2018-06-11 |
2024-05-30 |
Amgen Inc. |
KRAS G12C inhibitors for treating cancer
|
AU2019336588B2
(en)
|
2018-06-12 |
2022-07-28 |
Amgen Inc. |
KRAS G12C inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
|
MX2021000977A
(en)
|
2018-07-26 |
2021-04-12 |
Sumitomo Pharma Oncology Inc |
Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same.
|
JP2020090482A
(en)
|
2018-11-16 |
2020-06-11 |
アムジエン・インコーポレーテツド |
Improved synthesis of key intermediate of kras g12c inhibitor compound
|
JP7377679B2
(en)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
Combination therapy comprising a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer
|
EP3883565A1
(en)
|
2018-11-19 |
2021-09-29 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
CN109912490B
(en)
*
|
2018-11-30 |
2020-10-16 |
深圳大学 |
Indole compound Plannyindole E and preparation method thereof
|
EP3890749A4
(en)
|
2018-12-04 |
2022-08-03 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
|
ES2953821T3
(en)
|
2018-12-20 |
2023-11-16 |
Amgen Inc |
KIF18A inhibitors
|
US20220056015A1
(en)
|
2018-12-20 |
2022-02-24 |
Amgen Inc. |
Kif18a inhibitors
|
WO2020132653A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
US11236069B2
(en)
|
2018-12-20 |
2022-02-01 |
Amgen Inc. |
KIF18A inhibitors
|
KR20210146290A
(en)
|
2019-02-12 |
2021-12-03 |
스미토모 다이니폰 파마 온콜로지, 인크. |
Formulations comprising heterocyclic protein kinase inhibitors
|
AU2020232616A1
(en)
|
2019-03-01 |
2021-09-09 |
Revolution Medicines, Inc. |
Bicyclic heterocyclyl compounds and uses thereof
|
EP3931195A1
(en)
|
2019-03-01 |
2022-01-05 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
US11793802B2
(en)
|
2019-03-20 |
2023-10-24 |
Sumitomo Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (AML) with venetoclax failure
|
WO2020198077A1
(en)
|
2019-03-22 |
2020-10-01 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Compositions comprising pkm2 modulators and methods of treatment using the same
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
US11236091B2
(en)
|
2019-05-21 |
2022-02-01 |
Amgen Inc. |
Solid state forms
|
JP2022542394A
(en)
|
2019-08-02 |
2022-10-03 |
アムジエン・インコーポレーテツド |
Heteroarylamides useful as KIF18A inhibitors
|
CN114391012A
(en)
|
2019-08-02 |
2022-04-22 |
美国安进公司 |
Pyridine derivatives as KIF18A inhibitors
|
CA3146693A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
RU2734495C1
(en)
*
|
2019-09-13 |
2020-10-19 |
Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) |
Method of treating diabetes mellitus
|
WO2021081212A1
(en)
|
2019-10-24 |
2021-04-29 |
Amgen Inc. |
Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
|
CN115873020A
(en)
|
2019-11-04 |
2023-03-31 |
锐新医药公司 |
RAS inhibitors
|
CN114867735A
(en)
|
2019-11-04 |
2022-08-05 |
锐新医药公司 |
RAS inhibitors
|
KR20220100903A
(en)
|
2019-11-08 |
2022-07-18 |
레볼루션 메디슨즈, 인크. |
Bicyclic heteroaryl compounds and uses thereof
|
IL292315A
(en)
|
2019-11-14 |
2022-06-01 |
Amgen Inc |
Improved synthesis of kras g12c inhibitor compound
|
AU2020383535A1
(en)
|
2019-11-14 |
2022-05-05 |
Amgen Inc. |
Improved synthesis of KRAS G12C inhibitor compound
|
EP4058465A1
(en)
|
2019-11-14 |
2022-09-21 |
Cohbar Inc. |
Cxcr4 antagonist peptides
|
EP4065231A1
(en)
|
2019-11-27 |
2022-10-05 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
TW202140011A
(en)
|
2020-01-07 |
2021-11-01 |
美商銳新醫藥公司 |
Shp2 inhibitor dosing and methods of treating cancer
|
WO2021155006A1
(en)
|
2020-01-31 |
2021-08-05 |
Les Laboratoires Servier Sas |
Inhibitors of cyclin-dependent kinases and uses thereof
|
IL299131A
(en)
|
2020-06-18 |
2023-02-01 |
Revolution Medicines Inc |
Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
|
US11945809B2
(en)
|
2020-07-19 |
2024-04-02 |
King Saud University |
Isatin derivatives
|
MX2023002248A
(en)
|
2020-09-03 |
2023-05-16 |
Revolution Medicines Inc |
Use of sos1 inhibitors to treat malignancies with shp2 mutations.
|
PE20231207A1
(en)
|
2020-09-15 |
2023-08-17 |
Revolution Medicines Inc |
INDOLIC DERIVATIVES AS RAS INHIBITORS IN CANCER TREATMENT
|
CN117396472A
(en)
|
2020-12-22 |
2024-01-12 |
上海齐鲁锐格医药研发有限公司 |
SOS1 inhibitors and uses thereof
|
AR125782A1
(en)
|
2021-05-05 |
2023-08-16 |
Revolution Medicines Inc |
RAS INHIBITORS
|
AU2022268962A1
(en)
|
2021-05-05 |
2023-12-14 |
Revolution Medicines, Inc. |
Ras inhibitors for the treatment of cancer
|
EP4334324A1
(en)
|
2021-05-05 |
2024-03-13 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
IT202100023357A1
(en)
|
2021-09-09 |
2023-03-09 |
Cheirontech S R L |
Peptides with anti-angiogenic activity
|
AR127308A1
(en)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
RAS INHIBITORS
|
WO2023081923A1
(en)
|
2021-11-08 |
2023-05-11 |
Frequency Therapeutics, Inc. |
Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
|
WO2023114954A1
(en)
|
2021-12-17 |
2023-06-22 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
WO2023158785A1
(en)
*
|
2022-02-21 |
2023-08-24 |
University Of Houston System |
Small molecules that treat or prevent viral infections
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
WO2024081916A1
(en)
|
2022-10-14 |
2024-04-18 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|